Related Experiment Video
Updated: Jun 3, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
25.7K
Sirolimus Release from Biodegradable Polymers for Coronary Stent Application: A Review
Wei Xu1, Makoto Sasaki1,2, Takuro Niidome1
1Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan.
Pharmaceutics
|March 26, 2022
Summary
Biodegradable polymers in drug-eluting stents (DESs) improve safety by controlling sirolimus release, reducing thrombosis. Understanding polymer properties is key for developing effective DES treatments for coronary artery disease.
Area of Science:
- Biomaterials Science
- Cardiovascular Medicine
- Polymer Chemistry
Background:
- Drug-eluting stents (DESs) are crucial for treating coronary artery disease.
- Biodegradable polymers offer an advantage in DESs by minimizing late thrombosis.
- Controlling sirolimus release from these polymers is vital for stent safety and efficacy.
Purpose of the Study:
- To review sirolimus release from biodegradable polymers used in DESs.
- To highlight the impact of polymer properties on drug release kinetics.
- To provide insights for developing safer and more effective DESs.
Main Methods:
- Literature review focusing on sirolimus release from synthetic and natural biodegradable polymers.
- Analysis of key polymer properties influencing drug release (molecular weight, composition, Tg, crystallinity, degradation rate).
- Examination of the relationship between sirolimus release, endothelialization, and thrombosis.
Main Results:
- Biodegradable polymers are essential for controlled sirolimus elution in DESs.
- Polymer characteristics significantly dictate sirolimus release profiles.
- Optimized sirolimus release is linked to improved endothelialization and reduced thrombosis.
Conclusions:
- Biodegradable polymers represent a significant advancement in DES technology.
- Further research into polymer-drug interactions will enhance DES performance.
- This review consolidates current knowledge on sirolimus release for future DES development.
Related Concept Videos
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...